Evaluation of narrow band ultraviolet B phototherapy in the treatment of chronic actinic dermatitis in Chinese patients

Ma, Li; Zhang, Qiaoan; Y, Hu; Luo, Xiaoqun

doi:10.1111/dth.12528

Cited by 13 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Management of chronic actinic dermatitis and photo-dermatoses is involved in strict sun protection, photoprotective clothing, UVA, and UVB protective sunscreen (physical or sunscreen) but also includes topical and systemic corticosteroids and PUVA therapy. Narrowband ultraviolet B (NB UVB) phototherapy has shown remarkable therapeutic effects and a safety profile in Chinese patients ( 7 ). Azathioprine, cyclosporine, mycophenolate mofetil, and hydroxyurea are the steroid-sparing agents that have efficacy in CAD.…”

Section: Discussionmentioning

confidence: 99%

Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series

Ali

Lou

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Chronic actinic dermatitis (CAD) is a rare chronic immunological photo-dermatosis resulting in pruritic eczematous eruption on sun-exposed skin to ultraviolet (UV) light. The disease mechanism may include a delay-type hypersensitivity reaction to an endogenous photo-induced antigen, postulated to be UVR-altered DNA, but the exact pathophysiology is unknown. Minimum erythema dosing and patch testing are diagnostic tools of CAD. There are limited safe and effective treatment options for CAD. Herein, a case series of three patients with severe recalcitrant CAD is presented after being treated with dupilumab off-label. The patients in this study had persistent severe disease and taken the first-line management plan, which consists of topical calcineurin inhibitors (TCI), topical corticosteroids (TCS), and strict photoprotection. However, the above treatment options were not able to control the symptoms. The patients were treated with dupilumab 600 mg first dose, 300 mg biweekly subcutaneously (SC), and hydroxychloroquine. Dupilumab showed excellent clinical benefits, including safe and well-tolerated in chronic actinic dermatitis. Further studies are required to be carried out before being applied in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series

Ali

Lou

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Management is centered around strict photoprotection but also includes the use of topical and systemic corticosteroids, TCI, azathioprine, cyclosporine, mycophenolate mofetil, hydroxychloroquine, and PUVA therapy 1 . A report from China showed that narrowband UVB hardening therapy was beneficial in their patients 5 . Our case series indicates that dupilumab may be a viable option for CAD that has proven refractory to standard therapies.…”

Section: Discussionmentioning

confidence: 79%

Dupilumab for the treatment of chronic actinic dermatitis

Patel

Konda

Lim

2020

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

Dupilumab for the treatment of chronic actinic dermatitis 1 | INTRODUC TI ON Chronic actinic dermatitis (CAD) is an immune-mediated photodermatosis characterized by chronic, pruritic, eczematous, and often lichenified plaques distributed primarily upon sun-exposed skin. 1 The pathophysiology is believed to involve a delayed-type hypersensitivity reaction to an endogenous, photoinduced, cutaneous antigen, which has been speculated to be DNA. 1 First-line management options include strict photoprotection, topical corticosteroids (TCS), and topical calcineurin inhibitors (TCI). However, these are rarely sufficient on their own. Thus, many systemic therapies are often utilized with varying degrees of success. Dupilumab is a human monoclonal antibody that was initially approved in the United States for moderate-to-severe atopic dermatitis (AD); similar to CAD, AD is characterized by chronic, eczematous, pruritic skin lesions. Only one case of the use of dupilumab for the treatment of CAD has previously been reported. 2 Herein, we present five therapeutically challenging cases of CAD which were successfully managed with dupilumab.

show abstract

“…Chronic actinic dermatitis (CAD), synonymous with photosensitive dermatitis and actinic reticuloid syndrome, is a spectrum of diseases with chronic photosensitivity occurring mostly among middle‐aged and older men. It is characterized by eczematous lesions, mainly in sun‐exposed areas 1 . Although the exact mechanism of CAD has not been fully elucidated, the etiology of CAD is generally thought to be a delayed‐type allergy to both endogenous photoallergens and exogenous allergens.…”

Section: Introductionmentioning

confidence: 99%